In Canada, the sales of systemic hormonal preparations, excluding sex hormones and insulins, show a steady increase from 2024 to 2028, with the value consistently rising from 13.8 to 14.4 US Dollars Per Capita. Over these five years, the year-on-year growth rate remains modest, averaging around 1.1% annually. Compared to the actual data of 2023, this gradual upward trend indicates a stable demand for these products.
Future trends to watch for:
- Potential advances in hormonal therapy technologies could drive new product introductions.
- Healthcare policy changes affecting drug pricing or insurance coverage may impact sales growth.
- Demographic shifts, such as an aging population, could increase demand for certain hormonal preparations.
